Editas Medicine (EDIT) Tops Q3 EPS by 5c

Editas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.59), $0.05 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $962 thousand versus the consensus estimate of $960 thousand.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Editas Medicine grants stock options to new chief medical officer
• JPMorgan Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral